Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Announcing the new Tapestri Solution for Solid Tumor Oncology Research. Learn More


CHIP’ing away at somatic mosaicism — Diving into the promises and challenges of characterizing clonal hematopoiesis of indeterminate potential

April 22, 2022

CHIP (clonal hematopoiesis of indeterminate potential) is a non-malignant condition characterized by mutational and clonal expansion of hematopoietic stem cells, beginning at middle age. Though CHIP is not considered a disease, it is associated with a higher risk for several diseases including hematological malignancies, cardiovascular diseases and many others. Approximately 20% of the US population have this condition, but most are not aware of it. Understanding the causes and mechanisms of CHIP and how these cells interact with cells of other tissues will provide critical insights into disease development and evolution.

In this panel discussion webinar, speakers will discuss the growing interest in this topic and a few example studies looking at how this condition arises and transforms into a disease. Dr. Ross Levine of Memorial Sloan Kettering Cancer Center (MSKCC) will first discuss the clinical manifestations of clonal hematopoiesis, and mechanisms underlying its development as well as its role in clonal evolution toward leukemia. Then he will invite two other speakers, Dr. Kelly Bolton of Washington University of St. Louis and Dr. Jyoti Nangalia of Wellcome Sanger Institute, for an interactive panel discussion that will offer key insights and diverse perspectives on CHIP as an important risk factor and its clinical impact.


• Ross L. Levine, MD, Memorial Sloan Kettering Cancer Center
• Kelly Bolton, MD, PhD, Washington University of St. Louis
• Jyoti Nangalia, PhD, Wellcome Sanger Institute

11:30AM Eastern Daylight Time
Ross Levine, MD, MSKCC; Kelly Bolton, MD, PhD, Washington University in St. Louis; Jyoti Nangalia, PhD, Wellcome Sanger Institute